Coldstream Capital Management Inc. Raises Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Coldstream Capital Management Inc. raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 45.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,253 shares of the medical device company’s stock after purchasing an additional 3,508 shares during the quarter. Coldstream Capital Management Inc.’s holdings in DexCom were worth $781,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in DXCM. ORG Partners LLC lifted its stake in DexCom by 1,992.0% in the second quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock worth $59,000 after purchasing an additional 498 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in DexCom by 2.0% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 27,268 shares of the medical device company’s stock valued at $3,092,000 after acquiring an additional 547 shares during the period. Swedbank AB boosted its holdings in DexCom by 5.0% in the second quarter. Swedbank AB now owns 185,575 shares of the medical device company’s stock valued at $21,040,000 after purchasing an additional 8,795 shares during the last quarter. Pure Financial Advisors LLC boosted its stake in shares of DexCom by 38.2% in the second quarter. Pure Financial Advisors LLC now owns 2,276 shares of the medical device company’s stock worth $258,000 after buying an additional 629 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in shares of DexCom by 128.8% during the 2nd quarter. Blue Trust Inc. now owns 881 shares of the medical device company’s stock worth $100,000 after purchasing an additional 496 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ:DXCM opened at $78.93 on Friday. The company’s 50-day moving average is $73.58 and its two-hundred day moving average is $84.99. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm has a market capitalization of $30.83 billion, a price-to-earnings ratio of 47.26, a PEG ratio of 2.38 and a beta of 1.12.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on DXCM shares. Sanford C. Bernstein raised their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. JPMorgan Chase & Co. lifted their price objective on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Citigroup lifted their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $98.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.